According to Chris Mason 2006 heralded the era of Regenerative Medicine 2.0 (RegenMed2.0), where the focus is almost exclusively on the translation of research into commercially successful products.
‘While Web 1.0 was about commerce, Web 2.0 is about people and their active participation. The same is true for regenerative medicine; the pioneers were all about the science and research and little about translation into genuine products with benefits to both patients and shareholders. Whereas RegenMed2.0 is almost exclusively focused on the pragmatic translation of great science into routine clinical practice.’
Is he right? Or is his analysis too optimistic?
Why not find out more about how regenerative medicine is progressing..
This meeting is coming up and I am sure will address some of your questions
Future Advances in Regenerative Medicine
Friday, June 13, BioPark Hertfordshire
”Cell- and gene-based therapies are quickly progressing from the lab bench to the clinic. Restoration of damaged tissues in humans thus requires close and significant interactions between basic scientists, clinicians, regulators, biochemical and tissue engineers, and commercial biotechnology. The goal of this meeting is to provide a “snapshot” of the current landscape in Regenerative Medicine, and to highlight outstanding issues in translational biology”. Chair: Dr Stephen Minger, Kings College, UK.
Speakers:
Professor Glyn Stacey, National Institute of Biological Standards and Control, UK
Dr Rike Zietlow, Cardiff University, UK
Dr Paul Kemp, Chief Scientific Officer, Intercytex, UK
Dr Gillian Farnie, Paterson Institute for Cancer Research, UK
Dr Lyle Armstrong, Centre For Stem Cell Biology & Developmental Genetics International Centre For Life, UK
Dr Julie T Daniels, Director, Moorfields Eye Hospital Cells for Sight Tissue Bank, UK
Professor Nureddin Ashammakhi, Keele University, UK
To book a place at this meeting please click here . The deadline for early (reduced rate) registration is March 20th 2008.